Sutro Biopharma (NASDAQ:STRO) Will Have To Spend Its Cash Wisely
AI Sentiment
Negative
2/10
as of 01-06-2026 3:29pm EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 85.0M | IPO Year: | 2018 |
| Target Price: | $18.29 | AVG Volume (30 days): | 105.4K |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.23 - $21.50 | Next Earning Date: | 11-06-2025 |
| Revenue: | $105,646,000 | Revenue Growth: | -34.36% |
| Revenue Growth (this year): | 63.08% | Revenue Growth (next year): | -55.43% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
AI Sentiment
Negative
2/10
See how STRO stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.